<DOC>
	<DOCNO>NCT02145507</DOCNO>
	<brief_summary>This study evaluate new blood collection filtration system intend use collect , filter , separate store red blood cell , separately , plasma . The new blood collection filtration system compare already-approved currently use system . Further , study evaluate new processing condition relative individual component collection filtration system . All study participant donate two unit whole blood individual unit donate least 56 day apart . One unit whole blood donate new system , unit collect already-approved system . A subset donor ( approximately 24 120 participant ) small quantity red blood cell inject back body 42-days donated order evaluate well red blood cell survive . Blood blood product donor analyze day collection storage ( plasma least 30 day storage red blood cell exactly 42 day storage ) .</brief_summary>
	<brief_title>Evaluation Whole Blood With CPD Anticoagulant AS-7/SOLX Additive Solution</brief_title>
	<detailed_description>In vitro vivo performance SOLX® RBCs produce modify SOLX® System use demonstrate acceptability propose product modification expand indication . To accomplish , study require total 120 evaluable donor complete study . Enrolled donor assign either two study arm . Each study arm entail randomize , pair , 2-x-2 crossover design every study donor ( n = 60 evaluable study donor complete study per arm ) donate total two whole blood unit individual unit donate least 56 day ( 8 week ) apart . One unit collect investigational product ( IP ) unit collect control product ( CP ) . The order IP CP use collect , filter store whole blood appropriate blood product ( within context crossover design ) randomize . Each two study arm evaluate outcome result different storage , filtration processing condition : - Arm 1 entail hold whole blood unit 20-24°C collection ≥ 20 hour ( IP ) ≥ 6 hour ( CP ) prior initiate room temperature filtration . Following room temperature centrifugation subsequent separation , SOLX® PRBC place 1-6°C plasma place ≤ -18°C within 24 hour ( IP ) within 8 hour ( CP ) collection . The first donation occur product indicate per randomization second donation occur product alternate randomization . Arm 1 entail vivo double-radiolabelled autologous RBC recovery substudy ( n = 20-24 , pair IP CP data collect ) evaluation pre- post-rejuvenation PRBC 2,3-DPG level ( IP CP unit ) . The vivo substudy rejuvenation evaluation limit Arm 1 include Arm 2 . - Arm 2 entail hold whole blood unit 1-6°C collection ≥ 66 hour ( IP CP ) prior initiate cold filtration . Following refrigerated centrifugation subsequent separation , SOLX® PRBCs place 1-6°C within 72 hour collection ( IP CP ) . Plasma evaluate arm discard . The first donation occur product indicate per randomization second donation occur product alternate randomization . For study arm meet protocol-defined vitro acceptance criterion exactly 1 unit , additional 71 evaluable donor enrol , thus increase number evaluable enrolled donor complete respective study arm 131 donor . Only acceptance criterion endpoint meet within respective study arm evaluate neither matched/paired crossover control vivo RBC recovery ( Arm 1 In vivo substudy ) evaluate . If protocol define vitro acceptance criterion meet &gt; 1 subject meet protocol define vitro acceptance criterion relative specific study arm , enrollment occur relative study arm .</detailed_description>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Age Study donor must ≥ 18 year age Weight Study donor must ≥ 110 pound Temperature Study donor 's body temperature must ≤ 37.5°C / 99.5°F ( oral ) Hemoglobin Study donor 's hemoglobin must ≥12.5 g/dL Hematocrit Study donor 's hematocrit must ≥ 38 % . Donor Eligibility Study donor must meet criterion per respective site 's Research Blood Donation Record ( BDR ) Prior Donation Study donor 's recent single RBC unit donation must ≥56 day prior study donation . Study donor 's recent double RBC unit donation must ≥ 112 day prior study donation Informed Consent Study donor must consent study participation review express understanding siterespective IRBapproved inform consent form prior undergo study related procedure Bloodborne Pathogens Study donor 's test result collect blood indicate risk transfusiontransmitted disease ( TTD ) Adverse Events Study donor must agree report adverse event time sign informed consent twentyfour hour follow end active study involvement Pregnancy Female study donor must pregnant , expect pregnant breastfeeding . Only female donor participate vivo portion study : Women childbearing age must pregnant determined negative pregnancy test prior reinfusion . If acceptable local procedure , postmenopausal surgically sterile woman may exempt pregnancy test requirement Exclusion criterion : Failure meet one criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Leukoreduction</keyword>
	<keyword>Red Blood Cell post-leukoreduction recovery</keyword>
	<keyword>Packed red blood cell post storage hemolysis</keyword>
	<keyword>Red blood cell recovery</keyword>
	<keyword>Plasma clot factor</keyword>
	<keyword>2,3-DPG rejuvenation</keyword>
</DOC>